Analysts Issue Forecasts for LENZ FY2026 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Equities researchers at William Blair issued their FY2026 earnings per share estimates for LENZ Therapeutics in a note issued to investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown anticipates that the company will earn ($2.89) per share for the year. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share.

LENZ Therapeutics (NASDAQ:LENZ) last released its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Several other research analysts also recently weighed in on LENZ. Citigroup boosted their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a report on Thursday. TD Cowen began coverage on LENZ Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $60.00 target price for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $41.67.

LENZ Therapeutics Stock Performance

Shares of LENZ opened at $26.49 on Friday. LENZ Therapeutics has a 1 year low of $14.42 and a 1 year high of $38.93. The company’s 50 day simple moving average is $24.15 and its 200 day simple moving average is $27.03. The company has a market capitalization of $728.50 million, a price-to-earnings ratio of -5.55 and a beta of 0.58.

Hedge Funds Weigh In On LENZ Therapeutics

A number of hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP purchased a new stake in LENZ Therapeutics during the 3rd quarter worth $246,000. Charles Schwab Investment Management Inc. boosted its position in shares of LENZ Therapeutics by 197.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after buying an additional 81,901 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of LENZ Therapeutics in the third quarter valued at about $743,000. MetLife Investment Management LLC purchased a new stake in shares of LENZ Therapeutics during the 3rd quarter valued at about $182,000. Finally, BBR Partners LLC lifted its position in LENZ Therapeutics by 100.0% during the 3rd quarter. BBR Partners LLC now owns 40,000 shares of the company’s stock worth $950,000 after acquiring an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.